Characterization of chromosomal rearrangements in hematological diseases using spectral karyotyping.

Microtubule breakage is not a major mechanism for resolving end-to-end chromosome fusions generated by telomere dysfunction during the early process of immortalization. Chromosoma (2007) 0.77

Spectral karyotyping: an unique technique for the detection of complex genomic rearrangements in leukemia. Transl Pediatr (2014) 0.75

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95

MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene (2003) 7.90

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood (2002) 4.35

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2008) 4.26

Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater (2011) 3.83

Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol (2005) 3.29

The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol (2011) 2.79

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood (2004) 2.77

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet (2010) 2.62

Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood (2009) 2.54

Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol (2008) 2.54

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood (2008) 2.46

Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell (2009) 2.39

Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol (2005) 2.36

The ion channel polycystin-2 is required for left-right axis determination in mice. Curr Biol (2002) 2.36

Clinical and diagnostic features of patients with suspected Klinefelter syndrome. J Androl (2003) 2.29

Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol (2006) 2.22

BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood (2010) 2.17

An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat Med (2008) 2.12

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol (2007) 2.09

Haemoglobin Noah Mehmet Oeztuerk (alpha(2) delta(2)143 (H21)His-->Tyr: A novel delta-chain variant in the 2,3-DPG binding site. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 2.05

Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol (2008) 2.01

Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood (2007) 1.99

Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol (2004) 1.96

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol (2012) 1.91

Genotype-phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21. Eur J Hum Genet (2008) 1.90

An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res (2003) 1.87

The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood (2007) 1.84

Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood (2007) 1.81

Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol (2003) 1.78

The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med (2002) 1.75

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol (2009) 1.73

Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. Blood (2011) 1.73

AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood (2005) 1.69

First report of prevalence of non-syndromic hereditary prosopagnosia (HPA). Am J Med Genet A (2006) 1.69

Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood (2002) 1.68

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood (2002) 1.68

Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica (2006) 1.64

A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group. Haematologica (2004) 1.63

High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol (2013) 1.60

Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma. J Cancer Res Clin Oncol (2005) 1.59

Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res (2005) 1.51

The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica (2004) 1.51

The K-Cl cotransporter KCC3 is mutant in a severe peripheral neuropathy associated with agenesis of the corpus callosum. Nat Genet (2002) 1.51

High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin Cancer Res (2004) 1.50

Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol (2003) 1.49

ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol (2009) 1.48

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol (2013) 1.46

Cryopreservation of sperm from adolescents and adults with malignancies. J Androl (2004) 1.46

The cyclin A1-CDK2 complex regulates DNA double-strand break repair. Mol Cell Biol (2004) 1.43

Loss of K-Cl co-transporter KCC3 causes deafness, neurodegeneration and reduced seizure threshold. EMBO J (2003) 1.42

S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res (2004) 1.41

Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. Haematologica (2008) 1.41

Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip. Blood (2007) 1.28

Workflow to improve patient recruitment for clinical trials within hospital information systems - a case-study. Trials (2008) 1.27

Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. J Clin Oncol (2012) 1.27

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood (2003) 1.23

Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol (2007) 1.22

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood (2012) 1.22

Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res (2005) 1.22

High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Blood (2012) 1.21

6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol (2003) 1.18

Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy. Int J Cancer (2005) 1.17

Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Blood (2005) 1.16

DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res (2007) 1.15

RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation. Blood (2004) 1.15

Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol (2013) 1.15

Identification of acute myeloid leukaemia associated microRNA expression patterns. Br J Haematol (2008) 1.13

Wnt signaling regulates transendothelial migration of monocytes. J Leukoc Biol (2006) 1.12

Signal transduction of oncogenic Flt3. Int J Hematol (2005) 1.12

Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer (2008) 1.12

Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography. Blood (2007) 1.12

Delayed processing of bone marrow samples reveals a prognostic pattern of NME mRNA expression in cytogenetically normal acute myeloid leukemia. Leuk Lymphoma (2012) 1.11

Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. Blood (2010) 1.11

Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood (2009) 1.10

The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer. Clin Cancer Res (2010) 1.09

Allelic heterogeneity in the COH1 gene explains clinical variability in Cohen syndrome. Am J Hum Genet (2004) 1.09

S100A2 induces metastasis in non-small cell lung cancer. Clin Cancer Res (2009) 1.09

Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res (2004) 1.07

Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. Curr Drug Targets (2007) 1.07

Identification of interaction partners and substrates of the cyclin A1-CDK2 complex. J Biol Chem (2004) 1.06

RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes. Haematologica (2012) 1.06

E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. Blood (2009) 1.05

Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. Haematologica (2007) 1.04

Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell cycle progression in somatic cells. Oncogene (2005) 1.04

Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia. Genes Chromosomes Cancer (2003) 1.04

Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet (2005) 1.03

Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica (2003) 1.03